rapidli
develop
worldwid
pandem
signific
health
econom
burden
current
approv
treatment
prevent
therapeut
strategi
hundr
clinic
studi
regist
intent
discov
effect
treatment
review
current
regist
intervent
clinic
trial
treatment
prevent
provid
overal
summari
insight
global
respons
past
two
decad
three
novel
pathogen
human
coronavirus
emerg
anim
reservoir
middl
east
respiratori
syndromerel
coronaviru
merscov
sever
acut
respiratori
syndrom
coronaviru
sarscov
recent
sever
acut
respiratori
syndrom
coronaviru
refer
three
led
global
health
emerg
signific
morbid
mortal
largest
outbreak
sarscov
affect
individu
global
associ
death
case
fatal
rate
overal
cost
global
economi
sarscov
estim
us
billion
us
billion
follow
first
identif
patient
sever
pneumonia
wuhan
provinc
china
novemb
spread
rapidli
affect
perman
inhabit
contin
greatest
pandem
modern
time
declar
public
health
emerg
intern
concern
directorgener
ii
march
date
submiss
affect
countri
territori
confirm
case
global
iii
associ
estim
mortal
iii
furthermor
humantohuman
transmiss
continu
apac
despit
escal
public
health
measur
current
estim
impact
worldwid
economi
us
trillion
rise
iv
current
approv
therapi
either
treatment
prevent
predict
number
case
set
rise
significantli
repres
prodigi
acut
unmet
medic
need
sever
nation
intern
research
group
work
collabor
varieti
prevent
therapeut
intervent
potenti
avenu
explor
includ
vaccin
develop
convalesc
plasma
interferonbas
therapi
smallmolecul
drug
cellbas
therapi
monoclon
antibodi
mab
howev
drug
therapi
develop
costli
time
process
high
attrit
rate
speed
normal
drug
develop
pathway
unaccept
context
current
global
emerg
therefor
consider
interest
repurpos
exist
drug
expedit
development
antivir
treatment
influenza
hepat
b
hbv
hepat
c
hcv
filovirus
allow
rapid
develop
swift
genom
sequenc
facilit
process
allow
comparison
merscov
sarscov
morbif
virus
strategi
identifi
sever
genom
region
interest
glossari
adalimumab
mab
target
immunosuppress
commonli
use
inflammatori
condit
antibodi
antibodi
program
cell
death
protein
inhibit
revers
immun
exhaust
use
oncolog
treatment
eg
melanoma
hiv
proteas
inhibitor
develop
ascleti
pharmaceut
aviptadil
vasodil
shortact
alphaadrenoreceptor
antagonist
azvudin
nucleosid
revers
transcriptas
inhibitor
efficaci
hcv
hiv
baloxavir
marboxil
polymeras
acid
endonucleas
inhibitor
approv
influenza
bevacizumab
mab
target
vascular
endotheli
growth
factor
vegf
bismuth
oral
medic
use
treatment
helicobact
pylori
evid
inhibit
sar
coronaviru
helicas
atpas
blind
experiment
procedur
particip
investig
care
provid
outcom
assessor
clinic
trial
unawar
treatment
arm
particip
receiv
studi
describ
number
role
blind
ie
singl
doubl
quadrupleblind
studi
blind
reduc
risk
bia
outcom
trial
carrimycin
macrolid
antibiot
therapeut
modul
specif
identif
highli
conserv
region
involv
viral
enzym
differ
pathogen
coronavirus
sinc
recommend
intern
committe
medic
journal
editor
icmj
clinic
trial
regist
publicli
avail
domain
may
consid
public
introduct
requir
initi
increas
clinic
trial
transpar
contribut
increas
number
trial
record
onlin
registri
clinicaltrialsgov
v
intern
clinic
trial
registri
platform
ictrp
vi
log
trial
registri
vastli
facilit
dissemin
inform
across
sever
domain
includ
intervent
methodolog
patient
group
outcom
measur
furthermor
event
nonpubl
result
mean
trial
inform
remain
freeli
avail
analysi
context
current
global
pandem
perform
analysi
onlin
registri
clinicaltrialsgov
v
tabl
main
text
data
intern
clinic
trial
registri
incorpor
variou
nation
registri
includ
australia
new
zealand
china
netherland
brazil
india
cuba
republ
korea
germani
iran
japan
sri
lanka
thailand
peru
also
clinicaltrialsgov
eu
clinic
trial
registri
intern
standard
randomis
control
trial
number
isrctn
xi
panafrican
registri
three
studi
includ
treatment
patient
intervent
prevent
infect
uninfect
patient
describ
within
trial
report
novel
nucleosid
analogu
interferon
alpha
cytokin
use
treatment
chronic
viral
infect
hbv
hcv
interferon
beta
cytokin
use
treatment
multipl
sclerosi
leflunomid
immunosuppress
use
treatment
rheumatoid
arthriti
lipoic
acid
antioxid
losartan
angiotensinii
receptor
antagonist
novaferon
recombin
interferonlik
protein
vitro
vivo
model
evid
potent
activ
compar
interferon
openlabel
studi
treatment
receiv
particip
known
particip
investig
oseltamivir
neuraminidas
inhibitor
licenc
influenza
b
treatment
pegasi
pegyl
interferon
alpha
polyinosinicpolycytidyl
acid
immunostimul
agonist
immunostimul
agonist
randomis
studi
trial
treatment
intervent
randomli
alloc
particip
randomis
reduc
risk
bia
trial
outcom
recombin
cytokin
use
cancer
immunotherapi
treatment
eg
melanoma
ribavirin
guanosin
analogu
antivir
agent
use
rang
morbif
viral
infect
eg
hcv
human
respiratori
syncyti
viru
lassa
viru
ruxolitinib
select
inhibitor
janu
kinas
type
use
within
haematolog
polycythaemia
vera
myelofibrosi
sildenafil
phosphodiesteras
type
inhibitor
vasodil
use
commonli
erectil
dysfunct
pulmonari
arteri
hypertens
sodium
aescin
saponin
extract
aesculu
hippocastanum
seed
investig
use
lung
injuri
sofosbuvirdaclatasvir
combin
mediat
use
treatment
hcv
sofosbuvir
nucleotid
prodrug
act
inhibitor
hcv
rnadepend
rna
polymeras
daclatasvir
hcv
inhibitor
sofosbuvirledipasvir
combin
mediat
use
treatment
hcv
ledipasvir
inhibitor
hcv
protein
stem
cell
educ
therapi
circul
patient
blood
cell
separ
follow
brief
cocultur
immun
cell
cordblood
stem
cell
return
educ
immun
cell
patient
circul
suramin
antitrypanosom
drug
use
treatment
african
trypanosomiasi
tetrandrin
bisbenzylisoquinolin
alkaloid
calcium
channel
blocker
antiinflammatori
immunosuppress
properti
thalidomid
antiangiogen
immunomodul
use
rang
haematolog
malign
includ
multipl
myeloma
teratogen
antiemet
caus
rang
birth
defect
phocomelia
ictrp
vi
eu
clinic
trial
regist
vii
cochran
central
regist
control
trial
viii
figur
collat
regist
therapeut
prevent
intervent
clinic
investig
hope
clarifi
current
investig
advanc
guid
potenti
futur
strategi
identifi
intervent
studi
focus
prevent
strategi
treatment
patient
figur
march
search
identifi
studi
focus
form
tradit
chines
medicin
tcm
includ
herbal
medicin
acupunctur
form
complementari
medicin
analys
due
lack
scientif
rational
inadequ
provis
inform
regard
activ
ingredi
limit
applic
mainstream
medic
practic
tabl
key
tabl
show
intervent
treatment
tabl
prevent
strategi
tabl
clinic
investig
briefli
mention
earlier
mani
studi
focus
repurpos
establish
antivir
therapi
especi
show
prior
efficaci
sarscov
merscov
combin
lopinavirritonavir
common
exploratori
antivir
appear
investig
studi
tabl
antivir
drug
function
proteas
inhibitor
use
extens
manag
howev
lopinavir
insuffici
oral
bioavail
signific
therapeut
activ
due
rapid
catabol
cytochrom
enzym
system
specif
isoenzym
thu
ritonavir
given
concomitantli
inhibit
significantli
boost
halflif
lopinavir
lopinavirritonavir
investig
efficaci
sarscov
found
effect
compar
histor
control
howev
efficaci
seen
randomis
openlabel
studi
see
glossari
lopinavirritonavir
versu
standard
care
patient
clinic
trial
number
recruit
target
state
particip
registri
tabl
signific
benefit
seen
either
overal
mortal
reduct
viral
load
author
highlight
sever
limit
includ
lack
treatment
blind
studi
particip
investig
awar
treatment
assign
thu
reduc
studi
object
multipl
ongo
studi
explor
lopinavir
ritonavir
none
utilis
doubleblind
methodolog
address
limit
remdesivir
novel
nucleotid
analogu
antivir
initi
develop
manag
ebola
marburg
virus
howev
efficaci
rang
pathogen
virus
includ
sarscov
merscov
vitro
vivo
model
much
interest
molecul
follow
treatment
first
case
subsequ
recoveri
usa
current
ten
regist
trial
take
place
global
investig
efficaci
tabl
antivir
sever
antivir
drug
investig
predomin
activ
variou
influenza
subtyp
rna
virus
includ
favipiravir
avigan
umifenovir
arbidol
triazavirin
tzv
baloxavir
marboxil
xofluza
mani
trial
focus
drug
typic
use
manag
rna
virus
hcv
hiv
includ
danoprevirritonavir
azvudin
sofosbuvirledipasvir
sofosbuvir
daclatasvir
darunavircobicistat
emtricitabinetenofovir
tabl
antivir
addit
studi
investig
util
antivir
interferonbas
treatment
interestingli
also
look
variou
differ
rout
administr
eg
nasal
antimalari
treatment
thirtyf
trial
investig
use
antimalari
drug
chloroquin
hydroxychloroquin
tabl
antimalari
chloroquin
found
signific
inhibitori
effect
viral
cell
entri
replic
vitro
earli
report
clinic
experi
patient
report
benefici
clinic
virolog
outcom
chloroquin
treatment
recent
nonrandomis
openlabel
studi
examin
effect
hydroxychloroquin
eu
clinic
trial
number
vii
recruit
target
state
particip
registri
report
cohort
patient
report
signific
reduct
nasopharyng
swab
viral
posit
day
inclus
hydroxychloroquin
group
compar
control
howev
deviat
registrydescrib
protocol
patient
design
control
six
patient
receiv
concurr
treatment
azithromycin
prevent
bacteri
superinfect
select
patient
receiv
azithromycin
base
clinic
judgement
subgroup
receiv
azithromycin
neg
viral
swab
day
compar
hydroxychloroquin
alon
control
studi
limit
lack
randomis
blind
small
sampl
size
much
interest
chloroquin
hydroxychloroquin
treatment
studi
regist
tabl
antimalari
howev
four
report
use
robust
thymosin
thymu
hormon
stimul
develop
cell
tranilast
antiallerg
analogu
tryptophan
metabolit
inflammasom
inhibitor
triazavirin
guanin
nucleotid
analogu
broadspectrum
antivir
effect
umifenovir
arbidol
nonnucleosid
antivir
membran
fusion
inhibitor
licens
russia
treatment
influenza
key
tabl
tabl
doubleblind
randomis
control
protocol
investig
efficaci
evid
hyperinflammatori
respons
significantli
contribut
mortal
infect
corticosteroid
previous
triall
sarscov
howev
result
inconclus
advers
effect
associ
seven
regist
studi
evalu
effect
corticosteroid
tabl
immunosuppress
also
interest
drug
tocilizumab
use
treatment
rheumatoid
arthriti
seven
regist
trial
immunosuppress
investig
includ
adalimumab
antitnf
eculizumab
sarilumab
ixekizumab
fingolimod
receptor
modul
use
multipl
sclerosi
meplazumab
inhibit
cell
chemotaxi
also
viru
cell
entri
preprint
studi
patient
compar
control
origin
recruit
target
report
improv
clinic
virolog
outcom
convers
sever
studi
investig
immun
stimul
includ
antibodi
camrelizumab
recombin
antivir
peptid
immunomodulatori
function
fusion
protein
prevent
tolllik
receptor
tlr
activ
activ
immunosuppress
siglec
signal
recombin
human
granulocyt
colonystimul
factor
rhgcsf
investig
nonpharmaceut
intervent
modul
immun
system
use
cytokin
filtrat
devic
oxiri
cytosorb
reduc
circul
cytokin
inflammatori
mediat
tabl
cytokin
remov
cell
plasmabas
therapi
twentyfour
regist
studi
plan
investig
role
mesenchym
stem
cell
msc
tabl
cellbas
therapi
msc
immunomodulatori
tissu
repair
effect
secret
cytokin
growth
factor
previous
examin
phase
trial
adult
respiratori
distress
syndrom
ard
given
death
respiratori
failur
msc
postul
benefici
effect
far
one
studi
msc
recruit
target
state
particip
registri
report
result
seven
patient
show
improv
clinic
inflammatori
outcom
compar
three
control
patient
treat
salin
studi
plan
recruit
particip
patient
treatment
msc
control
salin
arm
use
plasma
patient
recov
potenti
benefit
provid
diseasespecif
neutralis
antibodi
target
therapi
develop
ebola
outbreak
advis
use
convalesc
plasma
wholeblood
therapi
howev
nonrandomis
compar
studi
patient
ebola
found
associ
improv
surviv
current
regist
trial
investig
convalesc
plasma
immunoglobulin
tabl
plasmabas
therapi
altern
treatment
strategi
variou
treatment
strategi
current
investig
includ
antifibroticinflammatori
agent
pirfenidon
use
treatment
idiopath
pulmonari
fibrosi
antiangiogen
agent
bevacizumab
antivegf
thalidomid
tabl
antifibrot
antiangiogen
five
studi
aim
assess
therapeut
util
modifi
gut
microbiom
tabl
microbiom
although
mechan
perform
explicit
trial
regist
ten
studi
investig
holist
approach
includ
physiotherapi
psycholog
nutrit
intervent
diseas
outcom
tabl
therapi
intervent
effect
vaccin
antivir
therapeut
agent
postexposur
prophylaxi
approv
prevent
infect
human
coronaviru
develop
vaccin
complex
timeconsum
process
high
attrit
rate
success
gener
vaccin
recent
flu
pandem
fuell
optim
toward
one
furthermor
rapid
genom
sequenc
insight
glean
vaccin
explor
merscov
sarscov
termin
due
success
diseas
contain
allow
preclin
anim
work
advanc
rapidli
novel
vaccin
estim
develop
howev
three
vaccin
studi
regist
phase
evalu
tabl
vaccin
two
studi
activ
recruit
usa
china
studi
newli
regist
initi
setup
modifi
mrna
vaccin
encod
viral
spike
protein
progress
rapidli
preclin
develop
human
test
day
sequenc
identif
develop
moderna
inc
nation
institut
allergi
infecti
diseas
niaid
howev
rapid
develop
prompt
safeti
concern
experienc
virologist
current
investig
vaccin
test
human
includ
replicativedefect
adenoviru
type
ncov
express
viral
protein
netherland
brazil
india
cuba
republ
korea
germani
iran
japan
sri
lanka
thailand
peru
also
clinicaltrialsgov
eu
clinic
trial
registri
intern
standard
randomis
control
trial
number
isrctn
panafrica
registri
lentivir
vector
system
express
viral
protein
immunomodulatori
gene
modifi
antigenpres
cell
aapc
tabl
vaccin
furthermor
postexposur
prophylaxi
attract
strategi
healthcar
worker
household
contact
expos
current
six
studi
look
use
antivir
umifenovir
antimalari
hydroxychloroquin
chloroquin
use
recombin
human
interferon
alpha
spray
prevent
infect
tabl
antivir
antimalari
clinic
trial
exclud
tcm
either
prevent
andor
treatment
regist
china
surpris
given
countri
saw
outbreak
diseas
first
first
clinic
trial
regist
within
month
identif
rapidli
expand
figur
public
health
initi
thu
far
success
curtail
previous
exponenti
growth
case
china
reduc
number
potenti
particip
clinic
trial
china
registr
new
clinic
trial
sinc
declin
furthermor
sever
studi
also
withdrawn
suspend
eg
wider
global
commun
slower
react
first
case
outsid
asia
report
late
januari
iii
subsequ
incid
increas
dramat
declar
europ
becom
new
diseas
epicentr
rise
total
number
case
ix
howev
recent
clinic
trial
regist
europ
figur
rapid
escal
trial
registr
respons
increas
diseas
incid
seen
china
unfortun
occur
europ
despit
encourag
sign
initi
focus
paneuropean
collabor
champion
european
union
prioriti
larger
patient
studi
compar
smaller
studi
regist
china
x
consequ
median
number
particip
european
regist
studi
particip
compar
china
usa
respect
exampl
chloroquin
postexposur
prophylaxi
plan
recruit
particip
tabl
howev
may
part
reflect
higher
proport
prevent
studi
current
carri
includ
larg
number
particip
hope
larger
studi
provid
higher
qualiti
evid
although
may
take
longer
gener
result
context
escal
public
health
crisi
increas
number
case
report
north
america
also
increas
clinic
trial
registr
usa
niaid
regist
first
usal
global
trial
midfebruari
utilis
site
across
asia
usa
figur
studi
regist
usa
gener
place
emphasi
larger
particip
number
china
tabl
adapt
trial
design
treatment
prevent
